Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
Zyla Life Sciences (ZCOR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/20/2020 |
8-K
| Investor presentation|
Docs:
|
"Assertio Completed Merger with Zyla Life Sciences Trading under ASRT on Nasdaq Global Select Market Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Upwards of $40 million in Expected Cost Synergies LAKE FOREST, Ill., -- Assertio Holdings, Inc., the successor issuer to Assertio Therapeutics, Inc., announced the closing of the merger with Zyla Life Sciences. The combined company will operate under the Assertio name and trade on Nasdaq under the ticker ASRT. The merger creates a growing commercial pharmaceutical company with neurology, inflammation and pain products. The Company now has a differentiated portfolio of non-steroidal anti-inflammatory drugs commonly used by neurologists, orthopedic surgeons, internists, women’ s health providers, podiatrists, p...",
"Presentation by Assertio Holdings, Inc." |
|
| 01/13/2020 |
8-K
| Investor presentation |
| 04/17/2019 |
8-K
| Quarterly results |
| 01/07/2019 |
8-K
| Quarterly results |
| 11/13/2018 |
8-K
| Investor presentation |
| 01/09/2017 |
8-K
| Form 8-K - Current report |
| 11/14/2016 |
8-K
| Investor presentation |
| 08/26/2016 |
8-K
| Form 8-K - Current report |
| 06/21/2016 |
8-K
| Form 8-K - Current report |
| 05/11/2016 |
8-K
| Form 8-K - Current report |
| 04/05/2016 |
8-K
| Form 8-K - Current report |
| 01/11/2016 |
8-K
| Form 8-K - Current report |
| 09/29/2015 |
8-K
| Form 8-K - Current report |
| 07/08/2015 |
8-K
| Form 8-K - Current report |
| 04/02/2015 |
8-K
| Form 8-K - Current report |
| 01/12/2015 |
8-K
| Form 8-K - Current report |
| 08/14/2014 |
8-K
| Form 8-K - Current report |
|
|